Replimune Group Inc (REPL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Replimune Group Inc (REPL) has a cash flow conversion efficiency ratio of -0.313x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-65.95 Million) by net assets ($210.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Replimune Group Inc for the company's overall valuation and market capitalisation.
Replimune Group Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Replimune Group Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Replimune Group Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Replimune Group Inc ranked by their cash flow conversion efficiency. See REPL operating cash flow to total debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing Fengshangshiji Culture Medi
SHE:300860
|
0.015x |
|
GMR Power and Urban Infra Limited
NSE:GMRP&UI
|
0.162x |
|
Sumber Tani Agung Resources Tbk PT
JK:STAA
|
0.115x |
|
Liberty Gold Corp
TO:LGD
|
-0.174x |
|
Zhejiang Changhua Auto Parts Co Ltd
SHG:605018
|
0.048x |
|
PHARMING GRP SP. ADRS
F:PHG
|
0.039x |
|
EuroTeleSites AG
F:7YF
|
N/A |
|
Newgen Software Technologies Limited
NSE:NEWGEN
|
0.050x |
Annual Cash Flow Conversion Efficiency for Replimune Group Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Replimune Group Inc from 2017 to 2025. View REPL stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $415.84 Million | $-192.25 Million | -0.462x | +6.65% |
| 2024-03-31 | $374.51 Million | $-185.47 Million | -0.495x | -114.76% |
| 2023-03-31 | $555.29 Million | $-128.05 Million | -0.231x | -15.39% |
| 2022-03-31 | $411.23 Million | $-82.18 Million | -0.200x | -62.35% |
| 2021-03-31 | $498.73 Million | $-61.39 Million | -0.123x | +62.65% |
| 2020-03-31 | $183.72 Million | $-60.55 Million | -0.330x | -79.04% |
| 2019-03-31 | $137.86 Million | $-25.38 Million | -0.184x | -132.27% |
| 2018-03-31 | $-28.07 Million | $-16.01 Million | 0.571x | -7.17% |
| 2017-03-31 | $-11.52 Million | $-7.08 Million | 0.615x | -- |
About Replimune Group Inc
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP… Read more